A five-year study investigating the use of micropulse transscleral cyclophotocoagulation (TSCPC) and how it affects intraocular pressure (IOP) in patients with glaucoma has been published in Ophthalmology and Therapy.

The authors judged micropulse TSCPC to be safe and effective as a treatment for reducing IOP and the number of IOP-lowering medications required. It was also deemed a viable alternative for patients after failed incisional glaucoma surgery. 

Researchers conducted a retrospective analysis of 165 patients with glaucoma in the Netherlands between 2016 and 2019. 

The study saw an IOP reduction or a stable postoperative IOP with fewer medications in 70.8% of patients after five years.